MedCity News
MARCH 14, 2023
Novo Nordisk can afford the price cuts prices to several branded and non-branded insulins. Flattening revenue for the pharmaceutical giant’s insulin products is offset by demand for diabetes and obesity drugs from its semaglutide franchise, which continues to grow by leaps and bounds.
Fierce Pharma
MARCH 16, 2023
AstraZeneca employees fight layoffs in India as drugmaker shifts 'strategic priorities' aliu Thu, 03/16/2023 - 09:54
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MARCH 15, 2023
The latest version of software tool MZmine, which aids analysis of mass spectrometry data, has been released. Using this third generation software, scientists can analyse large volumes of data from mass spectrometry, processing thousands of samples within minutes to hours. [the newest version can process] thousands of samples within minutes to hours.” It is the first tool with an entire data processing pipeline that integrates liquid chromatography (LC)-ion mobility spectrometry (IMS)-MS a
Medgadget
MARCH 17, 2023
Researchers at Linköping University in Sweden have developed a method whereby the body can ‘grow its own’ electrodes. The minimally invasive technique involves injecting a hydrogel that is laden with enzymes into target tissues. The enzymes interact with molecules that are present in the tissue to change the structure of the gel and allow it to become electrically conductive.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Pharmaceutical Technology
MARCH 14, 2023
The National Health Surveillance Agency (ANVISA) in Brazil has granted approval for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). The vaccine has received approval for preventing dengue disease in people aged four years to 60 years. Qdenga has been developed based on a live-attenuated dengue serotype 2 virus that offers the genetic backbone for four dengue virus serotypes and is designed to provide protection against any of these.
Fierce Pharma
MARCH 16, 2023
Novo Nordisk hit with two-year suspension from UK pharma group after online marketing breaches fkansteiner Thu, 03/16/2023 - 09:00
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
MARCH 17, 2023
Without a new set of tools that clinicians can access at the point of care, the availability of information from QHINs will increase provider burdens because they will struggle to find the information needed to evaluate a patient, take action, complete documentation, and move to the next patient.
Pharmaceutical Technology
MARCH 17, 2023
As the field of digital therapeutics continues to broaden, specific uses in mental health and neurology are increasingly making headway for patients and on the market. At the same time, experts are saying developers in the field need to double down on securing clinical data to allow for its continued maturation. Companies are testing the use of digital platforms along with pharmacological treatments.
Fierce Pharma
MARCH 13, 2023
With $43B buyout, Pfizer sees cancer specialist Seagen as a 'goose' laying 'golden eggs' kdunleavy Mon, 03/13/2023 - 10:16
European Pharmaceutical Review
MARCH 17, 2023
In a first-of-its-kind commercial agreement, Great Ormond Street Hospital NHS Foundation Trust (GOSH) will work with Leucid Bio to manufacture LEU011, a lateral Chimeric Antigen Receptor (CAR) targeting NKG2D ligands. The CAR T therapy will be used in clinical studies for solid tumours and haematological malignancies. Under the agreement the parties will work together at state-of-the-art cleanroom facilities at the Zayed Centre for Research into Rare Disease in Children.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
MARCH 16, 2023
Royalty Pharma’s milestone payment from the approval of Pfizer migraine drug Zavzpret stems from financing deals struck with the therapy’s previous developer, Biohaven Pharmaceuticals. Royalty Pharma is also in line to receive royalty payments going beyond the next decade.
Pharmaceutical Technology
MARCH 17, 2023
Pharmanovia and Aeterna Zentaris have entered an exclusive licensing agreement for the latter’s medicine Ghryvelin (macimorelin). Under the deal, Pharmanovia will acquire the exclusive rights and license to commercialise Ghryvelin in the EEA and the UK from Consilient Health. Ghryvelin is used for the diagnosis of Adult Growth Hormone Deficiency (AGHD), a rare and serious condition, as well as for Childhood Onset Growth Hormone Deficiency (CGHD), if approved.
Fierce Pharma
MARCH 17, 2023
Astellas, Pfizer look to broaden Xtandi’s patient base with new prostate cancer win after 8 years aliu Fri, 03/17/2023 - 10:22
European Pharmaceutical Review
MARCH 15, 2023
New targeted drug revumenib facilitated complete response in around 40 percent of patients with acute leukaemia subtypes, according to data in a new pair of studies ( 1 ) and ( 2 ) published in Nature. The two genetic subtypes of acute leukaemia involved in this research are “driven by a rearrangement of the MLL1 gene or a mutation in the NPM1 gene.
MedCity News
MARCH 14, 2023
Our challenges in the health space are too daunting for any single organization to tackle alone. We need to draw from both the strengths of the incumbents and the start-ups that have emerged in recent years, whether the challenge is in navigating care, simplifying care delivery, or fostering stronger patient engagement.
Pharmaceutical Technology
MARCH 16, 2023
Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio. The partnership will use nanotechnology, which was proven in vivo, for providing antibodies inside tumour cells and provides a potential solution to address the medical challenge.
Fierce Pharma
MARCH 14, 2023
Novo Nordisk follows Eli Lilly's lead, slashing insulin prices in the US kdunleavy Tue, 03/14/2023 - 10:56
Impetus Digital
MARCH 14, 2023
This is a guest article written by Luke Buchanan, CEO of Redi.Health , and does not necessarily reflect the views and values of Impetus Digital. When we think of adherence in the medical world, it’s often simplified to something along the lines of the degree to which a patient correctly follows medical advice. It’s a simple statement with many, many moving parts, especially when we’re talking about patients with multiple chronic conditions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
MARCH 15, 2023
Already, ChatGPT has been named as a co-author on at least four research papers. With proper management, AI generation could be an invaluable tool in clinical research—but only if we are mindful of the potential risks and biases that may arise from their usage and ensure transparency, fairness, and accountability in their use.
European Pharmaceutical Review
MARCH 17, 2023
The Medicines and Healthcare products Regulatory Agency (MHRA) ’s UK Stem Cell Bank is trialling an innovative new robot that grows stem cells. “The UK is only the second country where this technology has been tested” The MHRA’s UK Stem Cell Bank is testing the stem cell propagation robot over a 12-month period to see whether the cells produced by the fully automated Intelligent Cell Processing System meet the standards needed for them to be used in the manufacture of potentially life-savi
Fierce Pharma
MARCH 15, 2023
AbbVie's Humira, 5 Pfizer drugs among those with price hikes that exceeded inflation rate kdunleavy Wed, 03/15/2023 - 10:09
Pharmaceutical Technology
MARCH 17, 2023
The Lung Cancer Research Foundation (LCRF) has announced a new research partnership with Daiichi Sankyo and AstraZeneca. This collaboration is intended to fund up to three research grants that are focused on antibody-drug conjugates (ADCs) for improving the outcomes for lung cancer patients. ADCs are designed for targeting cancer cells specifically and selectively provide a highly potent payload that may limit healthy cells’ damage.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
MARCH 17, 2023
CMS should honor its commitment to Medicare beneficiaries, especially those who began home respiratory therapy under the PHE, without requiring them to “restart” the documentation process. Requiring requalification would also be a nightmare for physicians who are already overwhelmed with patient demands.
European Pharmaceutical Review
MARCH 17, 2023
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for VYVGART ® (efgartigimod alfa-fcab). It is the first neonatal Fc receptor (FcRn) blocker to be approved in the UK for adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. VYVGART is the first neonatal Fc receptor (FcRn) blocker to be approved in the UK for adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor
Fierce Pharma
MARCH 15, 2023
Pfizer adjusts EU vaccine deal but still wants payment for undelivered doses: FT esagonowsky Wed, 03/15/2023 - 08:43
Evolve Your Success
MARCH 14, 2023
They say luck is what happens when preparation meets opportunities. Daniel Tighe ’s enterprising story is a great example of how one can thrive under these circumstances. In this episode, he joins Samuel Adeyinka to share with us how he has been able to generate more business and become more successful in spine distributorship. He tells his entrepreneurial origin, shedding light on how he tackled the opportunities that came his way and approached marketing.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
MedCity News
MARCH 17, 2023
Perspectum — a company that makes medical imaging devices designed to improve the diagnosis of metabolic diseases and cancer — recently announced the second close of its $55 million Series C funding round. Its flagship product is a diagnostic tool that assesses and monitors chronic liver disease.
European Pharmaceutical Review
MARCH 16, 2023
The combination modulator therapy tezacaftor (TEZ) and ivacaftor (IVA) for cystic fibrosis (CF) has demonstrated long-term safety and clinical benefit in a four-year trial. The two CF modulators were assessed in patients 12 years and older. The participants tolerated the combination regimen over the course of the 96-week extension study. These patients had previously participated in a 120-day trial of the same combination.
Fierce Pharma
MARCH 16, 2023
Pfizer's Paxlovid gets thumbs-up for full approval from FDA advisory committee kdunleavy Thu, 03/16/2023 - 16:46
InCrowd
MARCH 15, 2023
Deborah Dropcho, PA After initial introductions with my new PA students, I always present them with my opening question. “What is the single greatest thing you can provide your patients?” Answers range from basic to insightful. Compassion and advocacy are two that I now hear often. The answer I am looking for is quite simple; Education. I tell both patients and students alike that if a health care provider does not educate their patients about lifestyle modifications; they are doing them a disse
Expert insights. Personalized for you.
98 
Let's personalize your content